These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 17080256)
1. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Mikkelsen T; Lush R; Grossman SA; Carson KA; Fisher JD; Alavi JB; Rosenfeld S Invest New Drugs; 2007 Jun; 25(3):259-63. PubMed ID: 17080256 [TBL] [Abstract][Full Text] [Related]
2. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Kohn EC; Reed E; Sarosy G; Christian M; Link CJ; Cole K; Figg WD; Davis PA; Jacob J; Goldspiel B; Liotta LA Cancer Res; 1996 Feb; 56(3):569-73. PubMed ID: 8564973 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. Hussain MM; Kotz H; Minasian L; Premkumar A; Sarosy G; Reed E; Zhai S; Steinberg SM; Raggio M; Oliver VK; Figg WD; Kohn EC J Clin Oncol; 2003 Dec; 21(23):4356-63. PubMed ID: 14645425 [TBL] [Abstract][Full Text] [Related]
4. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. Fetell MR; Grossman SA; Fisher JD; Erlanger B; Rowinsky E; Stockel J; Piantadosi S J Clin Oncol; 1997 Sep; 15(9):3121-8. PubMed ID: 9294475 [TBL] [Abstract][Full Text] [Related]
5. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Omuro A; Beal K; McNeill K; Young RJ; Thomas A; Lin X; Terziev R; Kaley TJ; DeAngelis LM; Daras M; Gavrilovic IT; Mellinghoff I; Diamond EL; McKeown A; Manne M; Caterfino A; Patel K; Bavisotto L; Gorman G; Lamson M; Gutin P; Tabar V; Chakravarty D; Chan TA; Brennan CW; Garrett-Mayer E; Karmali RA; Pentsova E J Clin Oncol; 2018 Jun; 36(17):1702-1709. PubMed ID: 29683790 [TBL] [Abstract][Full Text] [Related]
6. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. Kleinberg L; Grossman SA; Carson K; Lesser G; O'Neill A; Pearlman J; Phillips P; Herman T; Gerber M J Clin Oncol; 2002 Jul; 20(14):3149-55. PubMed ID: 12118029 [TBL] [Abstract][Full Text] [Related]
7. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499 [TBL] [Abstract][Full Text] [Related]
16. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era. Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327 [TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. Berlin J; Tutsch KD; Arzoomanian RZ; Alberti D; Binger K; Feierabend C; Dresen A; Marnocha R; Pluda J; Wilding G Clin Cancer Res; 2002 Jan; 8(1):86-94. PubMed ID: 11801543 [TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Dillman RO; Shea WM; Tai DF; Mahdavi K; Barth NM; Kharkar BR; Poor MM; Church CK; DePriest C Neuro Oncol; 2001 Jan; 3(1):35-41. PubMed ID: 11305415 [TBL] [Abstract][Full Text] [Related]
19. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S Oncology; 2012; 83(1):1-9. PubMed ID: 22688083 [TBL] [Abstract][Full Text] [Related]
20. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]